Paclitaxel-coated balloons and stents may pose less of a mortality risk than earlier studies indicated, a member of the board of directors of physician group VIVA told Medtech Insight.
A study published in the Journal of the American Heart Association (JAHA) in December 2018 found that peripheral arterial disease (PAD) patients who received devices coated with the drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?